Search results for "leukemia"

showing 10 items of 976 documents

Risk of childhood leukaemia and non-Hodgkin's lymphoma after parental occupational exposure to solvents and other agents: the SETIL Study

2013

AIM: In the context of the Italian Multicentric Epidemiological Study on Risk Factors for Childhood Leukaemia and Non-Hodgkin's Lymphoma (SETIL), the risk of childhood cancer was investigated in relation to parental occupational exposures. METHODS: All cases of childhood leukaemia and non-Hodgkin's lymphoma (NHL) in children aged 0-10 years were identified. Controls were chosen at random from the local population in each region. Parents were interviewed using a structured questionnaire. The collected data were blindly reviewed by expert industrial hygienists in order to estimate exposure to a list of agents. Statistical analyses were performed for each agent using unconditional multivariabl…

MaleToxicologyEconomicaPregnancyhemic and lymphatic diseasesEpidemiologyChildMultivariate Analysiparental exposureIncidenceLymphoma Non-HodgkinIncidence (epidemiology)Precursor Cell Lymphoblastic Leukemia-LymphomaOccupational exposureEpidemiologic StudieItalyMaternal ExposureChemical IndustryChild PreschoolPrenatal Exposure Delayed EffectsSolventPaternal ExposureFemaleSurvival AnalysiHYDROCARBONSCase-Control StudieRisk assessmentHumanmedicine.medical_specialtyLogistic ModelAdolescentSocio-culturaleContext (language use)Risk AssessmentPrenatal Exposure Delayed EffectHazardous SubstancesAge DistributionEnvironmental healthmedicineHumansSex DistributionSurvival analysisACUTE LYMPHOBLASTIC-LEUKEMIAbusiness.industryPublic Health Environmental and Occupational HealthCase-control studyAmbientalemedicine.diseaseSurvival AnalysisNon-Hodgkin's lymphomaEpidemiologic StudiesPaternal ExposureLogistic ModelssolventsHazardous SubstanceCase-Control StudiesMultivariate AnalysisbusinessOccupational and Environmental Medicine
researchProduct

Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

2014

Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; There are very few disease-specific studies focusing on outcomes of umbilical cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. We report the outcome of 45 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent myeloablative single unit cord blood transplantation from unrelated donors within the GETH/GITMO cooperative group. Conditioning regimens were based on combinations of thiotepa, busulfan, cyclophospamide or fludarabine, and antithymocyte globulin. At the time of transplantation, 35 patients (78%) were in first complete remission, four (8%) …

MaleTransplantation Conditioning:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings]Leucemia-linfoma linfoblástico de células precursorasGraft vs Host Disease:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]Supervivencia sin EnfermedadGastroenterology:Anatomy::Body Regions::Transplants::Allografts [Medical Subject Headings]:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Myeloablative Agonists [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]hemic and lymphatic diseasesMedicineCumulative incidenceTasa de SupervivenciaPhiladelphia ChromosomeChildCromosoma Filadelfia:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings]:Named Groups::Persons::Age Groups::Child::Child Preschool [Medical Subject Headings]ArticlesHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAllografts:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunosuppression::Transplantation Conditioning [Medical Subject Headings]FludarabineSurvival RateChild Preschool:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Chromosome Aberrations::Translocation Genetic::Philadelphia Chromosome [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Disease-Free Survival [Medical Subject Headings]FemaleAcondicionamiento para el trasplanteCord Blood Stem Cell TransplantationTrasplante de células madre de la sangre del cordónmedicine.drugAloinjertosAdultmedicine.medical_specialtyAdolescent:Check Tags::Male [Medical Subject Headings]Cord Blood Stem Cell TransplantationPhiladelphia chromosomeEnfermedad injerto contra huéspedDisease-Free SurvivalEstudios retrospectivosInternal medicine:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]HumansPreschoolSurvival rate:Named Groups::Persons::Age Groups::Child [Medical Subject Headings]Retrospective Studies:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Survival Rate [Medical Subject Headings]business.industryUmbilical Cord Blood TransplantationEnfermedad crónicaAgonistas mieloablativosMyeloablative Agonistsmedicine.diseaseSettore MED/15SurgeryTransplantation:Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings]:Diseases::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]Estudios de SeguimientoChronic Disease:Analytical Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures Operative::Transplantation::Cell Transplantation::Stem Cell Transplantation::Cord Blood Stem Cell Transplantation [Medical Subject Headings]Adolescent; Adult; Allografts; Child; Child Preschool; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Cord Blood Stem Cell Transplantation; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation ConditioningbusinessBusulfanFollow-Up Studies
researchProduct

Treatment-Induced Aggravation of Vasculitis in Hairy-Cell Leukemia

2020

MaleVasculitisLeukemia Hairy CellCancer ResearchPathologymedicine.medical_specialtybusiness.industryHematologyMiddle Agedmedicine.diseaseSteroid therapyOncologyHumansMedicineHairy cell leukemiaInfective complicationbusinessVasculitisCladribinemedicine.drugClinical Lymphoma Myeloma and Leukemia
researchProduct

Ultrasound Evaluation of Thyroid Gland Pathologies After Radiation Therapy and Chemotherapy to Treat Malignancy During Childhood.

2015

The purpose of this study was to evaluate correlations between treatment of malignancy by radiation therapy during childhood and the occurrence of thyroid gland pathologies detected by ultrasonography in follow-up examinations.Reductions of thyroid gland volume below 2 standard deviations of the weight-specific mean value, occurrence of ultrasonographically detectable thyroid gland pathologies, and hypothyroidism were retrospectively assessed in 103 children and adolescents 7 months to 20 years of age (median: 7 years of age) at baseline (1997-2013) treated with chemoradiation therapy (with the thyroid gland dose assessable) or with chemotherapy alone and followed by ultrasonography and lab…

Maleendocrine systemCancer Researchmedicine.medical_specialtyTime Factorsendocrine system diseasesAdolescentLymphomamedicine.medical_treatmentThyroid Gland030209 endocrinology & metabolismMalignancyCentral Nervous System Neoplasms03 medical and health sciences0302 clinical medicineHypothyroidismNeoplasmsmedicineHumansRadiology Nuclear Medicine and imagingChildRetrospective StudiesUltrasonographyUnivariate analysisChemotherapyAnalysis of VarianceRadiationLeukemiabusiness.industryCystsThyroidInfantRetrospective cohort studyChemoradiotherapyOrgan Sizemedicine.diseaseThyroid DiseasesLymphomaRadiation therapymedicine.anatomical_structureOncology030220 oncology & carcinogenesisChild PreschoolFemaleRadiologybusinessChemoradiotherapyFollow-Up StudiesStem Cell TransplantationInternational journal of radiation oncology, biology, physics
researchProduct

Testicular lymphoblastic leukemia/lymphoma

1995

Acute lymphoblastic leukemia is by far the most frequent malignant disease in children. In all, 5% of the boys affected will develop testicular disease either at initial presentation or during the disease course or as the first site of relapse. Modern treatment regimens have reduced the occurrence of testicular relapses, which was more frequent in the 1970s. There is no place for preventive measures for early recognition of testicular leukemia; routine biopsies have been abandoned, and prophylactic irradiation is not justified. In gross overt disease, orchiectomy is justified (1) in cases of huge bulky testicular disease, (2) if unilateral disease is probable, and (3) if radiation of the te…

Maleendocrine systemPediatricsmedicine.medical_specialtybusiness.industryLymphoma Non-HodgkinUrologymedicine.medical_treatmentLymphoblastic lymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyLymphomaSurgeryRadiation therapyTesticular LeukemiaTesticular diseaseLeukemiaTesticular NeoplasmsAcute lymphocytic leukemiamedicineHumansOrchiectomyChildbusinessWorld Journal of Urology
researchProduct

Synergistic effect of peplomycin in combination with bleomycin on L5178y mouse lymphoma cells in vivo.

1984

Studying the treatment of NMRI mice with ip injections of bleomycin (BLM) for 5 days we found an approximate LD50 of 35 mg/kg; the toxicity of peplomycin (PEP) was slightly higher (LD50: approximately 25 mg/kg). The effect of the two drugs on growth of L5178y mouse lymphoma cells in NMRI mice was examined. BLM alone caused at a concentration of 2.5 mg/kg an almost complete inhibition of tumor cell growth; the same effect was determined with 1 mg PEP/kg. At these concentrations the drugs caused an increase of the survival time of 110% (BLM) or 104% (PEP). Given in combination, one-sixth of the optimal doses yielded an 100% increase of the median survival time. These results indicate a signif…

Malemedicine.drug_classCell SurvivalAntibioticsPharmacologyBiologyBleomycinchemistry.chemical_compoundBleomycinMicePeplomycinIn vivoDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsLeukemia L5178PharmacologyLeukemia Experimentalurogenital systemCell growthMouse LymphomaBiological activityDrug SynergismchemistryToxicityImmunologyPeplomycinThe Journal of antibiotics
researchProduct

Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Behaviour before and during treatment acco…

1984

The thrombocyte count, the factor XIII (F XIII) activity, the concentration of fibrinogen (F I), prothrombin (F II), fibronectin (CIG), albumin and the proteinase inhibitors antithrombin III (AT III), alpha 2-macroglobulin (A2M), alpha 1-antitrypsin (A1A) and Cl-esterase inactivator (Cl-INA) were determined in ten children with acute lymphoblastic leukaemia (ALL). Changes due to the disease and to therapy were observed. Before the start of treatment the patients had thrombocytopenia secondary to the disease, and the proteinase inhibitors--especially Cl-INA and A1A--were raised. During the induction phase the thrombocyte count rose but there was also a marked increase in the concentration of…

Malemedicine.medical_specialtyAdolescentAntithrombin IIIAlpha (ethology)Complement C1 Inactivator ProteinsFibrinogenMaintenance therapyInternal medicineDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProtease Inhibitorsalpha-MacroglobulinsChildGenetics (clinical)Factor XIIIbusiness.industryAntithrombinAlbuminFibrinogenGeneral MedicineFactor XIIIMolecular medicineBlood Coagulation FactorsFibronectinsLeukemia LymphoidEndocrinologyCoagulationChild Preschoolalpha 1-AntitrypsinImmunologyMolecular MedicineFemaleProthrombinbusinessmedicine.drugKlinische Wochenschrift
researchProduct

Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes.

1999

Recurrent chromosomal abnormalities present in the malignant cells of children with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) often correlate closely with specific clinical and biologic characteristics of the disease. Certain unique cytogenetic rearrangements are associated with distinct morphologic leukemic subtypes. These rearrangements should be detectable in most children with AML and MDS with the use of complementary molecular techniques such as fluorescence in situ hybridization (FISH), Southern blotting, and polymerase chain reaction. Apart from the diagnostic assessment, cytogenetic findings sometimes predict clinical outcome and thus also serve as prognostic …

Malemedicine.medical_specialtyAdolescentOncogene Proteins FusionDiseasePatient Care PlanningTranslocation GeneticPolyploidyhemic and lymphatic diseasesBiomarkers TumorMedicineChromosomes HumanHumansChildChromosome Aberrationsmedicine.diagnostic_testbusiness.industryMyelodysplastic syndromesChildhood Acute Myeloid LeukemiaCytogeneticsMyeloid leukemiaInfantNeoplasms Second PrimaryHematologyGene rearrangementOncogenesmedicine.diseasePrognosisFusion proteinOncologyLeukemia MyeloidChild PreschoolMyelodysplastic SyndromesPediatrics Perinatology and Child HealthImmunologyAcute DiseaseCancer researchFemaleChromosome DeletionbusinessFluorescence in situ hybridizationJournal of pediatric hematology/oncology
researchProduct

Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia.

2001

Abstract Chronic lymphocytic leukemia (CLL) is a neoplastic disease susceptible to antioxidant enzyme alterations and oxidative stress. We have examined the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), and the oxidized/reduced glutathione (GSSG/GSH) ratio together with the levels of malondialdehyde (MDA) and 8-oxo-2′-deoxyguanosine (8-oxo-dG) in lymphocytes of CLL patients and compared them with those of normal subjects of the same age. SOD and CAT activity decreased in CLL lymphocytes while GPx activity increased. GSH content of CLL lymphocytes also increased, and GSSG concentration remained constant. Thus, a reduced GSSG/GSH ratio was obtaine…

Malemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentChronic lymphocytic leukemiamedicine.disease_causeBiochemistryAntioxidantsSuperoxide dismutasechemistry.chemical_compoundhemic and lymphatic diseasesPhysiology (medical)Internal medicineMalondialdehydemedicineHumansLymphocytesAgedchemistry.chemical_classificationGlutathione PeroxidasebiologySuperoxide DismutaseGlutathione peroxidaseDeoxyguanosineGlutathioneDNA NeoplasmMiddle AgedMalondialdehydemedicine.diseaseCatalaseGlutathioneLeukemia Lymphocytic Chronic B-CellEndocrinologychemistryBiochemistryCatalase8-Hydroxy-2'-Deoxyguanosinebiology.proteinFemaleLipid PeroxidationOxidoreductasesOxidative stressDNA DamageFree radical biologymedicine
researchProduct

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

2011

We conducted an international phase 2 trial to evaluate 2 dose levels of ofatumumab, a human CD20 mAb, combined with fludarabine and cyclophosphamide (O-FC) as frontline therapy for chronic lymphocytic leukemia (CLL). Patients with active CLL were randomized to ofatumumab 500 mg (n = 31) or 1000 mg (n = 30) day 1, with fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 days 2-4, course 1; days 1-3, courses 2-6; every 4 weeks for 6 courses. The first ofatumumab dose was 300 mg for both cohorts. The median age was 56 years; 13% of patients had a 17p deletion; 64% had β2-microglobulin > 3.5 mg/L. Based on the 1996 National Cancer Institute Working Group (NCI-WG) guidelines, the complete respo…

Malemedicine.medical_specialtyCyclophosphamideClinical Trials and ObservationsChronic lymphocytic leukemiaImmunologyMedizinNeutropeniaOfatumumabAntibodies Monoclonal HumanizedBiochemistryGastroenterologychemistry.chemical_compoundChemoimmunotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideCD20Chlorambucilbiologybusiness.industryAntibodies MonoclonalCell BiologyHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyLeukemia Lymphocytic Chronic B-CellNeoadjuvant TherapySurgeryFludarabineTreatment Outcomechemistrybiology.proteinFemaleImmunotherapybusinessVidarabinemedicine.drug
researchProduct